Dmitry Nosov

6.3k total citations · 1 hit paper
40 papers, 1.2k citations indexed

About

Dmitry Nosov is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Dmitry Nosov has authored 40 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 13 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Dmitry Nosov's work include Renal cell carcinoma treatment (29 papers), Cancer Genomics and Diagnostics (11 papers) and Renal and related cancers (10 papers). Dmitry Nosov is often cited by papers focused on Renal cell carcinoma treatment (29 papers), Cancer Genomics and Diagnostics (11 papers) and Renal and related cancers (10 papers). Dmitry Nosov collaborates with scholars based in Russia, United States and France. Dmitry Nosov's co-authors include Rustem Gafanov, Frédéric Pouliot, Elizabeth R. Plimack, Brian I. Rini, Thomas Powles, Ray McDermott, V.P. Stus, Bohuslav Melichar, Sérgio Jobim Azevedo and Ihor Vynnychenko and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Dmitry Nosov

35 papers receiving 1.1k citations

Hit Papers

Pembrolizumab plus axitinib versus sunitinib monotherapy ... 2020 2026 2022 2024 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
    2020 498 citations Thomas Powles, Elizabeth R. Plimack et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dmitry Nosov Russia 12 941 542 533 410 201 40 1.2k
Mariajosé Lechuga United States 12 570 0.6× 480 0.9× 269 0.5× 252 0.6× 148 0.7× 22 1.0k
Vahur Valvere Estonia 18 531 0.6× 784 1.4× 395 0.7× 388 0.9× 275 1.4× 27 1.4k
Jiří Tomášek Czechia 16 834 0.9× 680 1.3× 524 1.0× 418 1.0× 187 0.9× 61 1.4k
Gaetano Aurilio Italy 18 730 0.8× 725 1.3× 318 0.6× 529 1.3× 201 1.0× 65 1.4k
Beata Korytowsky United States 17 617 0.7× 565 1.0× 370 0.7× 250 0.6× 78 0.4× 78 1.1k
Alessia Mennitto Italy 19 479 0.5× 549 1.0× 271 0.5× 225 0.5× 212 1.1× 59 1.0k
Vladimir Vladimirov United States 12 677 0.7× 1.3k 2.4× 235 0.4× 300 0.7× 84 0.4× 25 1.6k
Matteo Rosellini Italy 14 673 0.7× 590 1.1× 389 0.7× 293 0.7× 203 1.0× 49 1.2k
Andrea Marchetti Italy 13 629 0.7× 564 1.0× 369 0.7× 276 0.7× 202 1.0× 48 1.2k
Sarita Dubey United States 22 792 0.8× 692 1.3× 489 0.9× 181 0.4× 160 0.8× 36 1.4k

Countries citing papers authored by Dmitry Nosov

Since Specialization
Citations

This map shows the geographic impact of Dmitry Nosov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dmitry Nosov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dmitry Nosov more than expected).

Fields of papers citing papers by Dmitry Nosov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dmitry Nosov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dmitry Nosov. The network helps show where Dmitry Nosov may publish in the future.

Co-authorship network of co-authors of Dmitry Nosov

This figure shows the co-authorship network connecting the top 25 collaborators of Dmitry Nosov. A scholar is included among the top collaborators of Dmitry Nosov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dmitry Nosov. Dmitry Nosov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2024). Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 42(16_suppl). 4505–4505. 8 indexed citations
2.
Nosov, Dmitry, et al.. (2023). Рак предстательной железы. Malignant tumours. 13(3s2-1). 640–660. 1 indexed citations
3.
Волкова, М. И., Dmitry Nosov, & B. Yа. Alekseev. (2023). Updates in urologic oncology guidelines: renal cell carcinoma. A review. SHILAP Revista de lepidopterología. 25(2). 151–154.
4.
Ivanov, Maxim, et al.. (2023). Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy. Frontiers in Oncology. 13. 1245547–1245547. 2 indexed citations
5.
Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2023). Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.. Journal of Clinical Oncology. 41(17_suppl). LBA4501–LBA4501. 45 indexed citations
6.
Powles, Thomas, Elizabeth R. Plimack, V.P. Stus, et al.. (2022). Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.. Journal of Clinical Oncology. 40(16_suppl). 4513–4513. 4 indexed citations
7.
8.
9.
10.
Tannir, Nizar M., Thomas Powles, Bernard Escudier, et al.. (2019). Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. Työväentutkimus Vuosikirja. 4(1). 29–39. 1 indexed citations
11.
Nosov, Dmitry, et al.. (2018). Potential biomarkers for nivolumab therapy of metastatic renal cell carcinoma. Cancer Urology. 14(1). 16–27.
12.
Molina, Ana M., Thomas E. Hutson, Dmitry Nosov, et al.. (2018). Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. European Journal of Cancer. 94. 87–94. 34 indexed citations
13.
Nosov, Dmitry, et al.. (2017). Analysis of changes in subpopulation of T-regulatory cells CD4+CD25+ in metastatic renal cell carcinoma. Russian Journal of Biotherapy. 16(2). 91–96. 1 indexed citations
14.
Nosov, Dmitry, et al.. (2015). Prognostic factors of the therapeutic efficacy of mTOR and VEGFR inhibitors in patients with metastatic renal cell carcinoma. SHILAP Revista de lepidopterología. 11(4). 34–41. 2 indexed citations
15.
Blay, Jean‐Yves, Lin Shen, Yoon‐Koo Kang, et al.. (2015). Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. The Lancet Oncology. 16(5). 550–560. 80 indexed citations
16.
17.
Nosov, Dmitry, et al.. (2014). Current idea of an algorithm for drug treatment and optimal succession of using targeted drugs. SHILAP Revista de lepidopterología. 2 indexed citations
18.
Nosov, Dmitry, Brooke Esteves, Oleg Lipatov, et al.. (2012). Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma. Journal of Clinical Oncology. 30(14). 1678–1685. 86 indexed citations
19.
Motzer, Robert J., Pankaj Bhargava, Mohammed Al-Adhami, et al.. (2011). A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 29(7_suppl). 310–310. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mariajosé Lechuga Breakdown of academic impact, for papers by Vahur Valvere Breakdown of academic impact, for papers by Jiří Tomášek Breakdown of academic impact, for papers by Gaetano Aurilio Breakdown of academic impact, for papers by Beata Korytowsky Breakdown of academic impact, for papers by Alessia Mennitto Breakdown of academic impact, for papers by Vladimir Vladimirov Breakdown of academic impact, for papers by Matteo Rosellini Breakdown of academic impact, for papers by Andrea Marchetti Breakdown of academic impact, for papers by Sarita Dubey
Rankless by CCL
2026